Mind Medicine (MindMed) Inc.
MNMD$515M
Small CapNASDAQMedicinal Chemicals & Botanical ProductsBiotechnology🇺🇸North AmericaNEW YORK74 employees
Mind Medicine (MindMed) Inc., doing business as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
May 15, 2026
9wMarket Overview
Stock performance and key metrics
MNMD News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
MM120 (LSD D-Tartrate)
Generalized Anxiety Disorder
MM-120
ADHD
MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
Autism Spectrum Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MM120 (LSD D-Tartrate) | Phase 3 | Generalized Anxiety Disorder | - | - |
MM-120 | Phase 2 | ADHD | - | - |
MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) | Phase 2 | Autism Spectrum Disorder | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply